Systemic Radiotherapy with Monoclonal Antibodies :
[Book]
Options and Problems
edited by Marie-Luise Sautter-Bihl, Heiner Bihl, Michael Wannenmacher.
Berlin, Heidelberg
Springer Berlin Heidelberg
1996
(ix, 198 pages 56 illustrations).
Recent results in cancer research, 141.
High dose radioimmunotherapy in malignant lymphoma --;Treatment of patients with recurrent malignant gliomas with intratumoral radioimmunoconjugates --;Two approaches for enhancing radioimmunotherapy: emitters and hyperthermia --;Use of epidermal growth factor receptor-425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant tratment of patients with high grade gliomas of the brain, treatment of diffuse leptomeningeal malignanca by intrathecal injection of 131I-radioimmunoconjugates --;Higher efficiency of 131I-labeled anti-carcinoembryonic antigen-monoclonal antibodies (Fab')2 as compared to intact antibodies in radioimmunotherapy of established human colon carcinoma grafted in nude mice --;Problems and advances in the dosimetry of radionuclide targeted therapy --;Experimental radioimmunotherapy: biological effectiveness and comparison with external beam radiation --;Monoclonal antibodies in tumor therapy --;Use of radioimmunotherapy in combination with bioreductive agents --;Optimal therapeutic strategies for radioimmunotherapy --;Minimal residual disease --;Can preirradiation enhance tumor uptake of radiolabled pharmaceuticals?
Almost a century ago Paul Ehrlich introduced the "magic bullet" concept of targeting therapeutic agents to specific tissues in order to reduce systemic toxicity.
Medicine.
Oncology.
Radiotherapy.
RC261
.
E358
1996
edited by Marie-Luise Sautter-Bihl, Heiner Bihl, Michael Wannenmacher.